GLATIRAMER ACETATE and DYSPNOEA

2,881 reports of this reaction

2.7% of all GLATIRAMER ACETATE reports

#7 most reported adverse reaction

Overview

DYSPNOEA is the #7 most commonly reported adverse reaction for GLATIRAMER ACETATE, manufactured by Teva Neuroscience, Inc.. There are 2,881 FDA adverse event reports linking GLATIRAMER ACETATE to DYSPNOEA. This represents approximately 2.7% of all 108,384 adverse event reports for this drug.

Patients taking GLATIRAMER ACETATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DYSPNOEA2,881 of 108,384 reports

DYSPNOEA is a less commonly reported adverse event for GLATIRAMER ACETATE, but still significant enough to appear in the safety profile.

Other Side Effects of GLATIRAMER ACETATE

In addition to dyspnoea, the following adverse reactions have been reported for GLATIRAMER ACETATE:

MULTIPLE SCLEROSIS RELAPSE — 5,118 reports
INJECTION SITE PAIN — 4,898 reports
DRUG INEFFECTIVE — 3,848 reports
INJECTION SITE REACTION — 3,485 reports
FATIGUE — 3,241 reports
MULTIPLE SCLEROSIS — 3,042 reports
FALL — 2,487 reports
INJECTION SITE ERYTHEMA — 2,440 reports
GAIT DISTURBANCE — 2,108 reports
INJECTION SITE MASS — 2,053 reports

Other Drugs Associated with DYSPNOEA

The following drugs have also been linked to dyspnoea in FDA adverse event reports:

0XYGEN ABEMACICLIB ABIRATERONE ACETATE ACALABRUTINIB ACETAMINOPHEN ACETAMINOPHEN 325 MG ACETAMINOPHEN 325MG ACETAMINOPHEN 500 MG ACETAMINOPHEN 500MG ACETAMINOPHEN AND CODEINE PHOSPHATE ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR, GUAIFENESIN, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE

Frequently Asked Questions

Does GLATIRAMER ACETATE cause DYSPNOEA?

DYSPNOEA has been reported as an adverse event in 2,881 FDA reports for GLATIRAMER ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DYSPNOEA with GLATIRAMER ACETATE?

DYSPNOEA accounts for approximately 2.7% of all adverse event reports for GLATIRAMER ACETATE, making it a notable side effect.

What should I do if I experience DYSPNOEA while taking GLATIRAMER ACETATE?

If you experience dyspnoea while taking GLATIRAMER ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

GLATIRAMER ACETATE Full Profile All Drugs Causing DYSPNOEA Teva Neuroscience, Inc. Drugs

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.